Sustained Clinical Benefits of Spiration Valve System in Patients with Severe Emphysema: 24-Month Follow-Up of EMPROVE.
Journal Information
Full Title: Ann Am Thorac Soc
Abbreviation: Ann Am Thorac Soc
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Pulmonary Medicine
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Author disclosures are available with the text of this article at www.atsjournals.org."
"Supported by Olympus Corporation. Olympus Corporation contributed to the trial design and review and clarification of the methods of the study. The contents of this article do not represent the views of the U.S. Department of Veterans Affairs or the U.S. government."
"Conclusions: SVS treatment resulted in statistically significant and clinically meaningful durable improvements in lung function, respiratory symptoms, and QOL, as well as a statistically significant reduction in dyspnea, for at least 24 months while maintaining an acceptable safety profile.: Clinical trial registered with www.clinicaltrials.gov (NCT 01812447)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025